Bio News
Germany-based Bayer said Kerendia has received approval from the US Food and Drug Administration (FDA) for adults with type 1 diabetes-associated chronic kidney disease.
In the phase 3 FINE-ONE trial, Kerendia reduced the urinary albumin-to-creatinine ratio (UACR) by at least 25% after 6 months.
Bayer forecasts that Kerendia’s peak annual sales will reach $3 billion (approximately 4 trillion won).
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
